NYSE Dojo - Learning Long Term Stocks Analysis

Deprecated: strripos(): Non-string needles will be interpreted as strings in the future. Use an explicit chr() call to preserve the current behavior in /home/customer/www/nysedojo.com/public_html/functions.php on line 913

PFE $53.91 One Year Performance +40.03%

Add To Watchlist

Pfizer Inc. Dr. Albert Bourla ER 07-26-22 12:30

See PFE Price Valuation

Sector	Healthcare	Beta	0.71	ETF	No	EPS	4.36
Industry	Drug Manufacturers—General	Last Div	1.58	52W Range	38.48-61.71	Mkt Cap	302,483,603,456
IPO Since	1944-01-17	Exchange	NYSE	PE	12.36	Shares	5,610,899,712

Who Has PFE

Profitability

Profitability Indicators Chart

Profit Margin Chart

	TTM	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Profitability Indicators
Revenue Per Share	16.44	14.51	7.54	9.29	9.14	8.8	8.68	7.91	7.82	7.57	7.93	8.63
Earning Per Share	4.44	3.92	1.73	2.92	1.9	3.57	1.18	1.13	1.44	3.23	1.96	1.28
Operating Cash Flow Per Share	6.16	5.82	2.59	2.26	2.7	2.76	2.61	2.35	2.66	2.61	2.29	2.59
Free Cash Flow Per Share	5.66	5.33	2.09	1.79	2.32	2.39	2.28	2.11	2.41	2.39	2.11	2.38
Book Value Per Share	14.67	13.78	11.38	11.34	10.8	11.94	9.78	10.48	11.24	11.2	10.92	10.51
Gross Profit Margin %	60.38	62.08	79.26	80.25	79.03	78.61	76.66	80.25	80.69	81.42	80.79	77.63
Operating Profit Margin %	27.59	24.89	20.9	26.9	28.04	26.85	25.99	26.56	27.21	31.73	30.5	26.96
Tax Rate %	8.01	7.62	6.36	7.83	5.94	-73.54	13.45	22.2	25.49	27.4	21.21	31.52
Net Profit Margin %	27.03	27.04	22.95	31.45	20.79	40.55	13.66	14.25	18.42	42.65	24.7	14.84
Profitability Growth (YoY)
Revenue Growth %	-	93.97	-19.02	-3.54	2.1	-0.53	8.13	-1.52	-3.84	-12.55	-12.52	-0.57
EPS Growth %	-	128.57	-40.91	45.91	-47.66	195.33	3.66	-23.81	-58.48	51.02	45.57	21.22
Operating Cash Flow Growth %	-	126.2	14.42	-20.47	-3.9	3.58	9.57	-14.04	-4.96	4.17	-15.74	76.71
Free Cash Flow Growth %	-	157.23	16.19	-26.68	-4.36	2.52	6.81	-14.93	-6.13	3.64	-15.36	86.9
BVPS Growth %	-	21.08	0.4	5	-9.6	22.14	-6.68	-6.73	0.32	2.57	3.85	-3.78
Compound Annual Growth Rate Chart (CAGR)		10Y CAGR	7Y CAGR	5Y CAGR	3Y CAGR
Revenue Per Share Growth % (CAGR)	-	6.23	9.05	10.52	16.02
Earning Per Share Growth % (CAGR)	-	7.18	19.45	1.89	10.31
Operating Cash Flow Per Share Growth % (CAGR)	-	9.78	13.83	16.09	37.07
Free Cash Flow Per Share Growth % (CAGR)	-	9.71	14.15	17.4	43.87
Book Value Per Share Growth % (CAGR)	-	2.35	3.99	2.91	6.71

PFE News Today

Pfizer (PFE) Gets Fast Track Designation for NASH Therapy

Pfizer (PFE) Gets Fast Track Designation for NASH Therapy

Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.

Zacks Investment Research 2022-05-27 15:04:06

A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?

A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?

Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.

Market Watch 2022-05-26 14:20:00

Pfizer says it will no longer make a profit from selling its patented drugs to 1.2 billion people in 45 low-income countries

Pfizer says it will no longer make a profit from selling its patented drugs to 1.2 billion people in 45 low-income countries

Pfizer will sell 23 drugs used to treat infectious and inflammatory diseases, cancers, and coronavirus at cost to low-income countries.

Business Insider 2022-05-26 07:38:04

Better Dividend Stock: Pfizer or Merck?

Better Dividend Stock: Pfizer or Merck?

It's a close call between these two big drugmakers.

The Motley Fool 2022-05-26 06:04:00

7 Undervalued Blue-Chip Stocks to Buy for June

7 Undervalued Blue-Chip Stocks to Buy for June

Undervalued blue-chip stocks can perform well in an ongoing market correction like today's, making these picks worth your time. The post 7 Undervalued Blue-Chip Stocks to Buy for June appeared first on InvestorPlace.

InvestorPlace 2022-05-25 18:54:57

Pfizer CEO downplays monkeypox outbreak fears: ‘I wouldn't worry much'

Pfizer CEO downplays monkeypox outbreak fears: ‘I wouldn't worry much'

Pfizer boss Albert Bourla said he isn't yet concerned about a widening monkeypox outbreak after confirmation of the first stateside case triggered alarm bells this week.

New York Post 2022-05-25 14:49:08

How Vaccine Cash Could Fuel Pfizer's Future Growth

How Vaccine Cash Could Fuel Pfizer's Future Growth

The drugmaker has a bold strategy to transform itself by 2030.

The Motley Fool 2022-05-25 11:33:57

Pfizer pledges not to make a profit on third world vaccines in future

Pfizer pledges not to make a profit on third world vaccines in future

Pfizer Inc (NYSE:PFE) has agreed to provide vaccines and other medicines to low-income countries around the world on a non-profit basis. The pharma group said it struck an accord at the World Economic Forum in Davos to provide all of its current and future patented vaccines and medicines on a “not-for-profit" basis to lower-income countries.

Proactive Investors 2022-05-25 11:02:08

Pfizer to sell low-cost COVID-19 vaccines in world's poorest countries

Pfizer to sell low-cost COVID-19 vaccines in world's poorest countries

Yahoo Finance reporter Anjalee Khemlani details how Pfizer is trying to maintain vaccine equity by offering various vaccines at a low cost in the world's poorest areas.

Yahoo Finance 2022-05-25 10:51:16

Pfizer (PFE) Reports More Positive Data From Etrasimod Study

Pfizer (PFE) Reports More Positive Data From Etrasimod Study

Pfizer (PFE) states that data from the ELEVATE 12 and ELEVATE 52 studies will form the basis of the regulatory submissions on etrasimod expected later this year

Zacks Investment Research 2022-05-25 10:02:37

>> read more PFE news